Foley Mark J 4
4 · Revance Therapeutics, Inc. · Filed Mar 19, 2024
Insider Transaction Report
Form 4
Foley Mark J
DirectorCEO
Transactions
- Tax Payment
Common Stock
2024-03-15$5.30/sh−17,228$91,395→ 994,935 total - Tax Payment
Common Stock
2024-03-15$5.30/sh−3,305$17,533→ 1,012,163 total
Holdings
- 110,913(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the "RSA") for 13,572 shares. The RSA vested in three equal annual installments from March 15, 2021.
- [F2]Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals.
- [F3]These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.